To Be Discontinued Tablet, Chewable Pulmonary/Allergy
Montelukast Sodium Tablet, C · 2 active FDA presentation rows for this drug
Brand: SINGULAIR
FDA lists Montelukast Sodium Tablet, C as To Be Discontinued (Organon).
No availability text on this FDA row.
Montelukast Sodium Tablet, Chewable: To Be Discontinued
FDA availability text is not recorded on this row. 2 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Montelukast Sodium Tablet, Chewable
- Manufacturer
- Organon
- Dosage Form
- Tablet, Chewable
- Presentation
- Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)
- Package NDC
- 78206-170-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 17, 2025
- Last Updated
- Nov 17, 2025
- Therapeutic Category
- Pulmonary/Allergy
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Full Drug Profile
montelukast
Side effects, interactions, warnings & more
Nearby, Other Montelukast Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.